Literature DB >> 23506905

Solute carriers (SLCs) in cancer.

Sara El-Gebali1, Susanne Bentz, Matthias A Hediger, Pascale Anderle.   

Abstract

During tumor progression cells acquire an altered metabolism, either as a cause or as a consequence of an increased need of energy and nutrients. All four major classes of macromolecules are affected: carbohydrates, proteins, lipids and nucleic acids. As a result of the changed needs, solute carriers (SLCs) which are the major transporters of these molecules are differently expressed. This renders them important targets in the treatment of cancer. Blocking or activating SLCs is one possible therapeutic strategy. For example, some SLCs are upregulated in tumor cells due to the increased demand for energy and nutritional needs. Thus, blocking them and turning off the delivery of fuel or nutrients could be one way to interfere with tumor progression. Specific drug delivery to cancer cells via transporters is another approach. Some SLCs are also interesting as chemosensitizing targets because blocking or activating them may result in an altered response to chemotherapy. In this review we summarize the roles of SLCs in cancer therapy and specifically their potential as direct or indirect targets, as drug carriers or as chemosensitizing targets.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23506905     DOI: 10.1016/j.mam.2012.12.007

Source DB:  PubMed          Journal:  Mol Aspects Med        ISSN: 0098-2997


  23 in total

1.  SLC7A11 Overexpression in Glioblastoma Is Associated with Increased Cancer Stem Cell-Like Properties.

Authors:  Monika D Polewski; Rosyli F Reveron-Thornton; Gregory A Cherryholmes; Georgi K Marinov; Karen S Aboody
Journal:  Stem Cells Dev       Date:  2017-07-27       Impact factor: 3.272

Review 2.  Molecular Imaging of Membrane Transporters' Activity in Cancer: a Picture is Worth a Thousand Tubes.

Authors:  Aniv Mann; Inessa Semenenko; Michal Meir; Sara Eyal
Journal:  AAPS J       Date:  2015-03-31       Impact factor: 4.009

3.  SLC46A1 Haplotype with Predicted Functional Impact has Prognostic Value in Breast Carcinoma.

Authors:  Viktor Hlavac; Radka Vaclavikova; Veronika Brynychova; Pavel Dvorak; Katerina Elsnerova; Renata Kozevnikovova; Karel Raus; Katerina Kopeckova; Sona Mestakova; David Vrana; Jiri Gatek; Pavel Soucek
Journal:  Mol Diagn Ther       Date:  2021-01-02       Impact factor: 4.074

Review 4.  SLC transporters as therapeutic targets: emerging opportunities.

Authors:  Lawrence Lin; Sook Wah Yee; Richard B Kim; Kathleen M Giacomini
Journal:  Nat Rev Drug Discov       Date:  2015-06-26       Impact factor: 84.694

5.  SLC5A3-Dependent Myo-inositol Auxotrophy in Acute Myeloid Leukemia.

Authors:  Yiliang Wei; Yu-Han Huang; Damianos S Skopelitis; Shruti V Iyer; Ana S H Costa; Zhaolin Yang; Melissa Kramer; Emmalee R Adelman; Olaf Klingbeil; Osama E Demerdash; Sofya A Polyanskaya; Kenneth Chang; Sara Goodwin; Emily Hodges; W Richard McCombie; Maria E Figueroa; Christopher R Vakoc
Journal:  Cancer Discov       Date:  2021-09-16       Impact factor: 38.272

6.  Molecular Changes in the Nasal Cavity after N, N-dimethyl-p-toluidine Exposure.

Authors:  June K Dunnick; B Alex Merrick; Amy Brix; Daniel L Morgan; Kevin Gerrish; Yu Wang; Gordon Flake; Julie Foley; Keith R Shockley
Journal:  Toxicol Pathol       Date:  2016-04-20       Impact factor: 1.902

7.  Defective quorum sensing of acute lymphoblastic leukemic cells: evidence of collective behavior of leukemic populations as semi-autonomous aberrant ecosystems.

Authors:  Sapan J Patel; Su Dao; Costel C Darie; Bayard D Clarkson
Journal:  Am J Cancer Res       Date:  2016-06-01       Impact factor: 6.166

8.  A Membrane Transporter Is Required for Steroid Hormone Uptake in Drosophila.

Authors:  Naoki Okamoto; Raghuvir Viswanatha; Riyan Bittar; Zhongchi Li; Sachiko Haga-Yamanaka; Norbert Perrimon; Naoki Yamanaka
Journal:  Dev Cell       Date:  2018-10-04       Impact factor: 12.270

Review 9.  A guide to plasma membrane solute carrier proteins.

Authors:  Mattia D Pizzagalli; Ariel Bensimon; Giulio Superti-Furga
Journal:  FEBS J       Date:  2020-09-18       Impact factor: 5.542

Review 10.  Mitochondrial Glutathione in Diabetic Nephropathy.

Authors:  Lawrence H Lash
Journal:  J Clin Med       Date:  2015-07-09       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.